Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

ENXTAM:ASM
ENXTAM:ASMSemiconductor

How Investors May Respond To ASM International (ENXTAM:ASM) Dividend Hike And €150 Million Buyback Plan

ASM International N.V. has reported its 2025 results, issued revenue guidance for 2026, proposed lifting its regular dividend to €3.25 per share, and authorized up to €150 million of share repurchases funded from excess cash. While fourth-quarter sales and earnings eased from the prior year, the combination of higher full-year profit, raised dividend, and new buyback plan signals confidence in the company’s cash generation and balance sheet strength. Next, we’ll examine how ASM...
TSE:2503
TSE:2503Beverage

Does Kirin’s Personalized Gut Microbiome Push Reshape Its Health-Nutrition Strategy (TSE:2503)?

Cowellnex, Kyowa Kirin and Metagen have begun joint research to develop gut microbiota tests and personalized food recommendation algorithms for Japanese individuals, using Cowellnex’s high-precision shotgun metagenomic data accumulated over roughly three years. The collaboration highlights how advanced microbiome analytics could underpin new personalized gut health services, potentially expanding Kirin’s reach in science-based health and nutrition solutions. Next, we’ll examine how this...
NasdaqGS:ERII
NasdaqGS:ERIIMachinery

A Look At Energy Recovery (ERII) Valuation After PX Q650 Desalination Launch

Why the PX Q650 launch matters for Energy Recovery (ERII) investors Energy Recovery (ERII) has drawn fresh attention after launching its PX Q650 Pressure Exchanger for desalination, combining higher flow capacity, very high stated efficiency, and extended warranties aimed at long-life plant operations. See our latest analysis for Energy Recovery. The PX Q650 launch comes on the heels of Energy Recovery’s recent earnings update. It arrives at a time when the stock has seen a 4.81% 1 day share...
NYSE:REZI
NYSE:REZIBuilding

Why Resideo Technologies (REZI) Is Down 7.5% After Mixed 2025 Results And Cautious 2026 Outlook – And What's Next

Resideo Technologies reported past fourth-quarter 2025 results with sales of US$1,895 million and net income of US$136 million, alongside full-year 2025 sales of US$7.47 billion but a net loss of US$527 million. The company also issued 2026 guidance calling for net revenue of US$1,866 million to US$1,890 million in the first quarter and US$7.80 billion to US$7.90 billion for the full year, highlighting a contrast between recent quarterly profitability and a loss-making full year. Against...
OM:ATCO A
OM:ATCO AMachinery

Will Atlas Copco (OM:ATCO A) Preserve Its Industrial Edge Through the 2026 Leadership Transition?

Atlas Copco Group announced that Henrik Elmin, Senior Executive Vice President and Business Area President for Industrial Technique since 2017, will leave the company in 2026 to focus on board work and industrial advisory roles, with his succession process starting immediately. Given Elmin’s long tenure and influence within Industrial Technique since joining in 2007, his planned departure raises important questions about continuity in leadership and business direction. We’ll now examine how...
NasdaqGS:NEOG
NasdaqGS:NEOGMedical Equipment

Is Neogen (NEOG) Pricing Make Sense After Mixed Share Performance This Year

If you are trying to figure out whether Neogen's current share price makes sense, you are not alone. A closer look at its valuation tools can help you frame that question more clearly. Neogen recently closed at US$9.70, with returns of a 13% decline over 7 days, a 10.2% decline over 30 days, a 38.6% gain year to date, and a 2.8% decline over the last year. This combination gives a mixed picture of how the market is currently pricing the stock. Recent coverage around Neogen has focused on the...
NZSE:SPK
NZSE:SPKTelecom

Does Spark’s Earnings Hit And Bigger Cost Cuts Change The Bull Case For Spark New Zealand (NZSE:SPK)?

Spark New Zealand reported in early 2026 that its adjusted EBITDA for the first half of FY2025 fell 15.5% year over year, prompting a reduction in full-year EBITDA guidance amid tougher economic conditions and a weaker enterprise mobile business. In response, Spark is launching a cost-cutting program targeting NZ$110–140 million in savings and pursuing long-term data center co-investments, while also working with other New Zealand telecom operators on shared fraud-prevention APIs to bolster...
NasdaqGS:ALLT
NasdaqGS:ALLTSoftware

How Investors May Respond To Allot (ALLT) Returning To Profitability With 2026 Revenue Growth Guidance

In February 2026, Allot Ltd. reported fourth-quarter 2025 sales of US$28.39 million and net income of US$2.9 million, alongside full-year 2025 sales of US$101.99 million and net income of US$3.71 million, marking a shift from a loss a year earlier. At the same time, the company guided for 2026 revenue of US$113 million to US$117 million, signaling management’s confidence in accelerating growth after its return to profitability. Next, we’ll examine how Allot’s return to profitability and...
NasdaqGS:INSG
NasdaqGS:INSGCommunications

Is Inseego's (INSG) Unified 5G Edge Strategy Deepening Its Moat or Stretching It Too Thin?

Inseego recently introduced the MiFi PRO M4 enterprise mobile router, built on its new ConnectOS software and Qualcomm’s Dragonwing MBB Gen 3 platform, while also unveiling an enhanced Inseego Subscribe SaaS BSS solution for complex enterprise and government subscriber lifecycle management. Together, these launches highlight Inseego’s push to create a unified wireless edge architecture that blends 5G hardware, cloud management, and enterprise-grade security into an integrated offering for...
ASX:ZIM
ASX:ZIMMetals and Mining

Zimplats Holdings (ASX:ZIM) Is Down 12.4% After Sharp Profit Rebound - Has The Bull Case Changed?

Zimplats Holdings Limited reported half-year results for the period ended December 31, 2025, with sales rising to US$641.75 million and net income to US$143.72 million, both sharply higher than a year earlier. The jump in basic earnings per share from US$0.04 to US$1.34 highlights a significant turnaround in profitability over the prior comparable period. We’ll now explore how this sharp rebound in profitability shapes Zimplats Holdings’ investment narrative and what it might mean for...
ASX:HLI
ASX:HLIDiversified Financial

Helia Group’s Valuation After Earnings Dividends And New Revenue Guidance

Why Helia Group is back on investor radars Helia Group (ASX:HLI) has drawn fresh attention after releasing its full year 2025 earnings, setting insurance revenue guidance for 2026, and declaring both an ordinary dividend and a sizeable special dividend. See our latest analysis for Helia Group. Despite a 2.68% one day share price decline and recent volatility around the A$5.81 level, Helia’s 39.48% one year total shareholder return and very large five year total shareholder return suggest...
NYSE:YALA
NYSE:YALAInteractive Media and Services

Assessing Yalla Group (YALA) Valuation After New US$150 Million Buyback And Q1 2026 Revenue Guidance

Why Yalla Group (YALA) is back on investors’ radar Yalla Group (YALA) has drawn fresh attention after its board approved a new share repurchase program of up to US$150 million, alongside first quarter 2026 revenue guidance that factors in the timing of Ramadan. See our latest analysis for Yalla Group. Those moves come after a period where the 1 year total shareholder return of 76.9% contrasts with a more muted 0.7% year to date share price return at US$7.11, suggesting recent momentum has...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Exact Sciences EHR Outreach Lifts CRC Screening And Fuels Investor Interest

Exact Sciences, Amalgam Rx and Privia Health report materially higher colorectal cancer screening rates using EHR-enabled outreach and at home noninvasive tests. The coordinated program is described as scalable and has surpassed national screening benchmarks during Colorectal Cancer Awareness Month. The initiative focuses on closing screening gaps by embedding screening prompts and workflows directly into clinical systems and patient communications. For investors watching NasdaqCM:EXAS,...
BME:ROVI
BME:ROVIPharmaceuticals

Assessing Laboratorios Farmaceuticos Rovi (BME:ROVI) Valuation After 2025 Results Dividend Hike And 2026 Guidance

Earnings, dividend proposal and guidance at a glance Laboratorios Farmaceuticos Rovi (BME:ROVI) has drawn fresh attention after releasing its 2025 results, proposing a higher cash dividend and reaffirming its 2026 operating revenue guidance. This provides investors with updated information on profitability and capital returns. See our latest analysis for Laboratorios Farmaceuticos Rovi. The earnings release and dividend proposal come after a strong run in the shares, with a 30 day share price...
TSX:SLVR
TSX:SLVRMetals and Mining

Is Silver Tiger Metals (TSXV:SLVR) Trading Higher Losses for a Clearer Project Strategy?

Silver Tiger Metals Inc. recently reported results for the third quarter and nine months ended December 31, 2025, posting a third-quarter net loss of C$1.93 million versus C$1.35 million a year earlier and a nine‑month net loss of C$3.66 million versus C$3.11 million. Although the basic loss per share from continuing operations held steady at C$0.01, the widening net loss may prompt investors to reassess how the company is managing its expenses and project pipeline. We will now look at how...
NYSE:ACCO
NYSE:ACCOCommercial Services

ACCO Brands (ACCO) Return To Profit Tests Bearish Earnings Narrative

ACCO Brands (ACCO) has reported its FY 2025 third quarter with revenue of US$383.7 million and EPS of US$0.04, alongside net income of US$4 million. The trailing 12 month figures show revenue of US$1.54 billion and EPS of US$0.44 supported by net income of US$40.6 million. Over recent quarters the company has seen revenue move from US$438.3 million with EPS of a US$1.29 loss and a net loss of US$125.2 million in Q2 2024 to US$394.8 million with EPS of US$0.32 and net income of US$29.2 million...
SWX:COPN
SWX:COPNPharmaceuticals

Cosmo Pharmaceuticals (SWX:COPN) Swings To Loss And Tests Bullish Profitability Narratives

Cosmo Pharmaceuticals (SWX:COPN) has kicked off FY 2025 with first half revenue of €51.7 million and a basic EPS loss of €0.13, following FY 2024 second half revenue of €130.6 million with basic EPS of €3.45 and first half 2024 revenue of €136.2 million with basic EPS of €4.42. Over the trailing twelve months in the data, revenue is €182.3 million with basic EPS of €3.68. Investors may focus on how the latest dip into a small loss fits against a period where margins and earnings have...
TASE:NYAX
TASE:NYAXElectronic

Nayax (TASE:NYAX) Profitability Turnaround Tests High 85.3x P/E Narrative

Nayax (TASE:NYAX) posts FY 2025 results Nayax (TASE:NYAX) has put up another busy quarter, with Q3 FY 2025 revenue at US$104.3 million and basic EPS of US$0.10, alongside trailing twelve month revenue of US$369.9 million and basic EPS of US$0.65. The company has seen revenue move from US$78.1 million in Q2 FY 2024 to US$104.3 million in Q3 FY 2025, while quarterly EPS has shifted from a loss of US$0.08 per share in Q2 FY 2024 to a profit of US$0.10 per share in Q3 FY 2025. This sets up a...
NasdaqGM:FCEL
NasdaqGM:FCELElectrical

FuelCell Energy (FCEL) Q4 Revenue Reaches US$55 Million Yet Losses Challenge Bullish Narratives

FuelCell Energy (FCEL) has opened Q1 2026 earnings season with Q4 2025 numbers that show total revenue of US$55.0 million and a basic EPS loss of US$0.85, alongside net income excluding extra items of a US$30.7 million loss. Over the past few quarters, the company has seen revenue move from US$23.7 million in Q3 2024 to US$49.3 million in Q4 2024 and then to US$55.0 million in Q4 2025. Quarterly basic EPS stayed in loss territory, ranging from a US$2.21 loss per share in Q4 2024 to a US$3.78...
TSXV:BRC
TSXV:BRCMetals and Mining

Is Blackrock Silver (TSXV:BRC) Balancing Permitting Progress and Financial Strain at Tonopah West?

In early March 2026, Blackrock Silver Corp. secured a five-year Class II Air Quality and Surface Disturbance Permit for its Tonopah West project in Nevada, allowing disturbance of up to 150 acres while it advances engineering, hydrogeological and geochemical work toward broader permitting targeted by mid-2027. Alongside this regulatory progress, the company has mobilized rigs for extensive resource expansion drilling at Tonopah West, underscoring a simultaneous push on permitting and...
NasdaqGS:SWBI
NasdaqGS:SWBILeisure

Does Smith & Wesson (SWBI) Earnings-Driven Dividend Stability Mask Deeper Profitability Pressures?

In early March 2026, Smith & Wesson Brands, Inc. reported that its third-quarter sales rose to US$135.71 million and net income to US$3.75 million, while affirming a quarterly dividend of US$0.13 per share payable on April 2, 2026. An interesting contrast is that, despite higher quarterly sales and earnings year on year, net income for the first nine months fell to US$2.26 million from US$4.79 million, highlighting pressure on profitability over the longer period. We’ll explore how the...
NYSE:GWRE
NYSE:GWRESoftware

Guidewire’s Record Quarter And Buyback Sharpen Focus On Cloud And AI

Guidewire Software (NYSE:GWRE) reported a strong quarter with record revenue and rising demand for its cloud and AI products. The company secured significant new cloud customer wins and saw broader uptake of its AI driven offerings across insurers. Management raised the full year outlook and authorized a $500 million share buyback program, signaling confidence in the business. For investors watching insurance technology, Guidewire sits at the center of core systems, cloud migration, and...
NasdaqGS:EDIT
NasdaqGS:EDITBiotechs

Editas Medicine (EDIT) Q3 Loss Improvement Tests Bearish Earnings Decline Narrative

Fresh off its FY 2025 third quarter update, Editas Medicine (EDIT) posted revenue of US$7.5 million with a basic EPS loss of US$0.28. Trailing 12 month figures show revenue of US$46.4 million and a basic EPS loss of US$2.35. Over recent quarters the company has seen revenue move from US$30.6 million in Q4 2024 to US$4.7 million in Q1 2025, US$3.6 million in Q2 2025 and US$7.5 million in Q3 2025. Basic EPS losses were US$0.55, US$0.92, US$0.63 and US$0.28 across those same periods as investors...
NasdaqGS:BLKB
NasdaqGS:BLKBSoftware

Blackbaud Bets On Agents For Good AI To Deepen Recurring Revenue

Blackbaud (NasdaqGS:BLKB) is introducing its new Agents for Good AI portfolio, focused on the social good sector. The first product, Development Agent, is already in paid early-adopter contracts ahead of general availability. The rollout signals a shift toward monetizing proprietary AI tools within Blackbaud's software suite. For you as an investor, this move sits at the intersection of software, AI and the social impact sector, where Blackbaud already has an established presence. Many SaaS...